Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib before reduced-intensity allogeneic stem cell transplantation in myelofibrosis
NL-OMON21596Phase 2Not yet recruiting
- Sponsor
- HOVON
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-essential thrombocythemia myelofibrosis (PET-MF) and 1 more, sponsored by HOVON. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-essential thrombocythemia myelofibrosis (PET-MF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on NL-OMON21596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21596.